These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
698 related articles for article (PubMed ID: 21777944)
21. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390 [TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844 [TBL] [Abstract][Full Text] [Related]
23. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer]. Wang YJ; Wang N; Wang B; Qin WX; Xue CY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082 [TBL] [Abstract][Full Text] [Related]
24. Increased expression of osteopontin in patients with triple-negative breast cancer. Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545 [TBL] [Abstract][Full Text] [Related]
25. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D Oncology; 2013; 84(3):150-7. PubMed ID: 23257904 [TBL] [Abstract][Full Text] [Related]
26. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951 [TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression]. Fan Y; Guan Y; Zhao WH; Li Q; Xu BH Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993 [TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Huang J; Tan PH; Thiyagarajan J; Bay BH Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061 [TBL] [Abstract][Full Text] [Related]
30. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study. Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762 [TBL] [Abstract][Full Text] [Related]
31. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer]. Ma JG; Wang NJ; Yu WJ Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778 [TBL] [Abstract][Full Text] [Related]
32. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Han JS; Cao D; Molberg KH; Sarode VR; Rao R; Sutton LM; Peng Y Am J Clin Pathol; 2011 Feb; 135(2):230-7. PubMed ID: 21228363 [TBL] [Abstract][Full Text] [Related]
33. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Francis G; Beadle G; Thomas S; Mengersen K; Stein S Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275 [TBL] [Abstract][Full Text] [Related]
35. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156 [TBL] [Abstract][Full Text] [Related]
37. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
38. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases. Gwin K; Wheeler DT; Bossuyt V; Tavassoli FA Int J Surg Pathol; 2010 Feb; 18(1):27-35. PubMed ID: 19282292 [TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N Oncology; 2013; 84(3):135-40. PubMed ID: 23235554 [TBL] [Abstract][Full Text] [Related]
40. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]